Indivior’s shares rise after US court blocks Dr Reddy’s generic drug

Indivior stuck to its 2018 revenue guidance on Friday but said it would revisit the forecast if Dr Reddy’s launches the cheaper drug

Powered by WPeMatico

Scroll to top